Tandvårds- och läkemedelsförmånsverket (TLV) har meddelat att ANDEMBRY® ska ingå i läkemedelsförmånerna från och med den 1 februari 2026. Subventionen är begränsad till rutinmässig prevention av recidiverande anfall av hereditärt angioödem (HAE) hos patienter i åldern 12 år och äldre med svår sjukdomsbild och minst fyra HAE-anfall i månaden.
Global biopharma leader CSL (ASX:CSL) today announced five-year (60-month) results from the pivotal Phase 3 HOPE-B study, confirming the long-term durability and safety of a one-time infusion of HEMGENIX® (etranacogene dezaparvovec) in adults living with moderate to severe haemophilia B. Published in the New England Journal of Medicine (NEJM).
Sverige ligger under EU-snittet i patienters tillgång till behandlingar för sällsynta sjukdomar och patienter i 20 europeiska länder har tillgång till fler särläkemedel. Resultatbaserade avtal där betalning kopplas till faktisk klinisk effekt kan minska ekonomiska risker och samtidigt bidra till kostnadsbesparingar och effektivare vård. Flera länder, som Danmark, har redan infört sådana modeller.
94% of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment. Mean factor IX activity levels were sustained at near normal levels of 37% through four years post-treatment, reinforcing the efficacy of HEMGENIX® in the treatment of haemophilia B.
Helena Bragd is the new General Manager of CSL Behring Nordic Region – Sweden, Denmark, Norway, Finland, and Iceland. CSL Behring is a global biotherapeutics leader driven by our promise to save lives.
CSL Behring Denmark today announced that the first Danish patients with haemophilia B were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec). HEMGENIX® is the first one-time gene therapy to be approved in Europe for the treatment of adults with severe and moderately severe haemophilia B.
CSL Behring today announced that an outcome-based agreement has been reached with Amgros, the Danish procurement authority, for the national reimbursement of HEMGENIX® in Denmark. Denmark is the first country in the Nordic region to reimburse HEMGENIX® under such a performance-based model, in which the regions only incur costs if the gene therapy proves effective over an agreed long-term period.
